APA (7th ed.) Citation

M, F., F, P., P, M., P, H., S, T., AK, S., & M, P. (2025). Reply to: Oligoclonality of TRBC1 and TRBC2 in T cell lymphomas as mechanism of primary resistance to TRBC-directed CAR T cell therapies. Nature communications, 16(1), 1103. https://doi.org/10.1038/s41467-025-56396-7

Chicago Style (17th ed.) Citation

M, Ferrari, Parekh F, Maciocia P, Horna P, Thomas S, Sewell AK, and Pule M. "Reply to: Oligoclonality of TRBC1 and TRBC2 in T Cell Lymphomas as Mechanism of Primary Resistance to TRBC-directed CAR T Cell Therapies." Nature Communications 16, no. 1 (2025): 1103. https://doi.org/10.1038/s41467-025-56396-7.

MLA (9th ed.) Citation

M, Ferrari, et al. "Reply to: Oligoclonality of TRBC1 and TRBC2 in T Cell Lymphomas as Mechanism of Primary Resistance to TRBC-directed CAR T Cell Therapies." Nature Communications, vol. 16, no. 1, 2025, p. 1103, https://doi.org/10.1038/s41467-025-56396-7.